Emery Salom
Overview
Explore the profile of Emery Salom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burke W, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye A, et al.
Gynecol Oncol
. 2014 Jun;
134(2):393-402.
PMID: 24929052
Endometrial carcinoma is the most common gynecologic malignancy. A thorough understanding of the epidemiology, pathophysiology, and management strategies for this cancer allows the obstetrician-gynecologist to identify women at increased risk,...
2.
Burke W, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye A, et al.
Gynecol Oncol
. 2014 Jun;
134(2):385-92.
PMID: 24905773
Endometrial carcinoma is the most common gynecologic malignancy. A thorough understanding of the epidemiology, pathophysiology, and management strategies for this cancer allows the obstetrician-gynecologist to identify women at increased risk,...
3.
Salom E, Penalver M, Homesley H, Burrell M, Garrett A, Presant C, et al.
J Transl Med
. 2012 Aug;
10:162.
PMID: 22873358
Background: This study was performed to determine if a chemotherapy-induced apoptosis assay (MiCK) could predict the best therapy for patients with ovarian cancer. Methods: A prospective, multi-institutional and blinded trial...
4.
Bosserman L, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, et al.
Cancer Res
. 2012 Aug;
72(16):3901-5.
PMID: 22865459
A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic...
5.
McCreath W, Salom E, Chi D
Surg Oncol Clin N Am
. 2005 Apr;
14(2):249-66.
PMID: 15817238
No abstract available.
6.
Lambrou N, Gomez-Marin O, Mirhashemi R, Beach H, Salom E, Almeida-Parra Z, et al.
Gynecol Oncol
. 2004 Jun;
93(3):653-8.
PMID: 15196860
Objective: To evaluate the survival impact of residual disease at the time of primary surgery for patients with Stage III and IV endometrial carcinoma; to assess morbidity associated with surgical...
7.
Mirhashemi R, Lamrbou N, Hus N, Salom E, Penalver M, Averette H
Gynecol Oncol
. 2004 Jan;
92(1):220-4.
PMID: 14751162
Objectives: To describe the gastrointestinal (GI) complications associated with the Miami Pouch (MP), a continent ileocolonic urinary reservoir. Methods: A retrospective chart review of patients who underwent a MP from...
8.
Mendez L, Mueller A, Salom E, Gonzalez-Quintero V
Obstet Gynecol
. 2003 Nov;
102(5 Pt 2):1200-2.
PMID: 14607056
Background: Ovarian cancer diagnosed during pregnancy is uncommon. Most chemotherapy use reported has been in combination with cisplatinum. Paclitaxel in combination with carboplatin during pregnancy has not yet been reported....
9.
Salom E, Almeida Z, Mirhashemi R
Curr Opin Oncol
. 2002 Aug;
14(5):519-27.
PMID: 12192271
In this era of advanced medical technology, recurrent ovarian cancer continues to be a therapeutic dilemma. Most of these patients will succumb to their disease process. For this reason, it...